Article Information
History
- December 14, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- David A. Swan1,†,
- Chloe Bracis2,†,
- Holly Janes1,
- Mia Moore1,
- Laura Matrajt1,
- Daniel B. Reeves1,
- Eileen Burns3,
- Deborah Donnell1,4,
- Myron S. Cohen5,
- Joshua T. Schiffer1,6,7,†† and
- Dobromir Dimitrov1,8,††,*
- 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA
- 2Université Grenoble Alpes, TIMC-IMAG / BCM, 38000, Grenoble, France
- 3Independent Researcher, Seattle, WA, USA
- 4Department of Global Health, University of Washington, Seattle, WA USA
- 5Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC USA
- 6Clinical Research Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA
- 7Department of Medicine, University of Washington, Seattle, WA, USA
- 8Department of Applied Mathematics, University of Washington, Seattle, WA, USA
- ↵*Corresponding author:
Dobromir Dimitrov, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N., M2-C200, P.O. Box 19024, Seattle, WA 98109-1024, USA, Office: 206.667.1933, Cell: 245.894.8537, E-mail: ddimitro{at}fredhutch.org
Posted December 14, 2020.
COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact
